Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. The company’s lead product candidate includes AN2728, anti-inflammatory product, which is in Phase III clinical trials for the treatment of mild-to-moderate atopic dermatitis and psoriasis. It is also developing AN2898, an anti-inflammatory product candidate, which has completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; AN3365, an antibiotic product candidate for the treatment of infections caused by Gram-negative bacteria; and AN2718, an antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin. The company has research collaborations with Drugs for Neglected Diseases initiative to develop new therapeutics for human African trypanosomiasis, visceral leishmaniasis, and Chagas disease; research and development collaboration with GlaxoSmithKline LLC for tuberculosis (TB); research, license, and commercialization agreement with Eli Lilly and Company for an animal health indication; and research agreement with The Bill & Melinda Gates Foundation for filarial worm diseases, TB, and cryptosporidiosis. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.